Baxdrostat (Baxfendy) — An Aldosterone Synthase Inhibitor for Hypertension
Baxdrostat (Baxfendy) — An Aldosterone Synthase Inhibitor for Hypertension
July 6, 2026 (Issue: 1758)
The FDA has approved baxdrostat (Baxfendy – AstraZeneca),
an oral aldosterone synthase inhibitor, for add-on treatment
of hypertension in adults whose blood pressure is not
adequately controlled on other drugs. Baxdrostat is the...more
- RM Carey et al. Resistant hypertension: detection, evaluation, and management: a scientific statement from the American Heart Association. Hypertension 2018; 72:e53. doi:10.1161/hyp.0000000000000084
- MC Acelajado et al. Treatment of resistant and refractory hypertension. Circ Res 2019; 124:1061. doi:10.1161/circresaha.118.312156
- Aprocitentan (Tryvio) for hypertension. Med Lett Drugs Ther 2024; 66:92.
- B Williams et al. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. Lancet 2015; 386:2059. doi:10.1016/s0140-6736(15)00257-3
- Drugs for hypertension. Med Lett Drugs Ther 2024; 66:81.
- E Mlynarska et al. Baxdrostat: a next-generation aldosterone synthase inhibitor offering new hope in resistant hypertension. Biomolecules 2025; 15:1439. doi:10.3390/biom15101439
- JM Flack et al. Efficacy and safety of baxdrostat in uncontrolled and resistant hypertension. N Engl J Med 2025; 393:1363. doi:10.1056/nejmoa2507109
- M Azizi et al. Effect of baxdrostat on ambulatory blood pressure in patients with resistant hypertension (Bax24): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet 2026; 407:988. doi:10.1016/s0140-6736(25)02549-8
- Inhibitors and inducers of CYP enzymes, P-glycoprotein, and other transporters. Med Lett Drugs Ther 2023 January 25 (epub). Available at: www.medicalletter.org/downloads/CYP_PGP_Tables. pdf.
- Approximate WAC. WAC = wholesaler acquisition cost or manufacturer's published price to wholesalers; WAC represents a published catalogue or list price and may not represent an actual transactional price. Source: AnalySource ® Monthly. June 5, 2026. Reprinted with permission by First Databank, Inc. All rights reserved. ©2026. www.fdbhealth.com/drug-pricing-policy.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.
Would you like to read the rest of this article? Gain access below.
Subscribe
Subscriptions to
The Medical Letter on Drugs and Therapeutics include:
- Print version published and mailed biweekly (26 issues/year)
- Unlimited online access to current and past issues (1988 - present)
- Mobile App
- FREE online per issue CME/CE
Purchase this article:
Title: Baxdrostat (Baxfendy) — An Aldosterone Synthase Inhibitor for Hypertension
Article code: 1758a
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
